Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by year of treatment initiation.

Total proportion of patients with MDR-TB after initial attempt at diagnosis and treatment, based on varying population INHR-TB prevalence.

Kamila Romanowski (6260870)
Jonathon R. Campbell (4543495)
Olivia Oxlade (66115)
Federica Fregonese (442412)
Dick Menzies (66118)
James C. Johnston (370579)

January 2019

Total proportion of patients with MDR-TB after initial attempt at diagnosis and treatment, based on ...

Percentage of patients with various TSAT levels in the last 3 months of three studies over 14 years from 1997 to 2011.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

Percentage of patients with various TSAT levels in the last 3 months of three studies over 14 yea...

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clinical stage (left) and CD4 cell count (right).

Fabienne Shumbusho (369912)
Johan van Griensven (333866)
David Lowrance (318136)
Innocent Turate (369913)
Mark A. Weaver (369914)
Jessica Price (369915)
Agnes Binagwaho (26709)

February 2013

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clin...

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by facility in the most recent years of data available.

Herbert C. Duber (712085)
Emily Dansereau (610260)
Samuel H. Masters (673005)
Jane Achan (145106)
Roy Burstein (673006)
Brendan DeCenso (673007)
Anne Gasasira (232652)
Gloria Ikilezi (673010)
Caroline Kisia (673011)
Felix Masiye (344814)
Pamela Njuguna (357242)
Thomas Odeny (712086)
Emelda Okiro (712087)
D. Allen Roberts (712088)
Emmanuela Gakidou (250582)

March 2015

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by facility in the most recent y...

Median CD4 (IQR) for patients initiated on ART, by adherence < or ≥95% based on drug-refill visits.

Ziad El-Khatib (354831)
David Katzenstein (182035)
Gaetano Marrone (239053)
Fatima Laher (238017)
Lerato Mohapi (158544)
Max Petzold (177356)
Lynn Morris (7883)
Anna Mia Ekström (102696)

February 2013

Median CD4 (IQR) for patients initiated on ART, by adherence < or ≥95...

First-line ART regimen by enrollment year, ARV-naïve patients (N = 70,002).

Seema T. Meloni (459667)
Charlotte A. Chang (3232419)
Geoffrey Eisen (3232416)
Toyin Jolayemi (3232422)
Bolanle Banigbe (3232410)
Prosper I. Okonkwo (3232413)
Phyllis J. Kanki (459676)

October 2016

First-line ART regimen by enrollment year, ARV-naïve patients (N = 70,002).</p

Mean CD4+ T-cell percentage (95% confidence interval) after ART initiation by regimen.

Janneke H. van Dijk (277226)
Catherine G. Sutcliffe (185370)
Francis Hamangaba (277227)
Christopher Bositis (277228)
Douglas C. Watson (277229)
William J. Moss (185392)

January 2013

Mean CD4+ T-cell percentage (95% confidence interval) after ART initiation by regimen....

Proportion of antiretroviral therapy (ART) initiation among patients attending HIV clinics in two U.S. cities as measured by ART prescriptions written before or within 7 days after index visit, August 1, 2015-March 31, 2017, by selected patient characteristics.

Mary Spink Neumann (5824034)
Aaron Plant (5433278)
Andrew D. Margolis (130004)
Craig B. Borkowf (226185)
C. Kevin Malotte (271544)
Cornelis A. Rietmeijer (5824037)
Stephen A. Flores (243186)
Lydia O’Donnell (5824040)
Susan Robilotto (5824043)
Athi Myint-U (5824046)
Jorge A. Montoya (5433272)
Marjan Javanbakht (3857254)
Jeffrey D. Klausner (307922)

October 2018

Proportion of antiretroviral therapy (ART) initiation among patients attending HIV clinics in two U....

Description of ART usage among 371 women who initiated treatment.

Eugene Mutimura (239330)
Donald R. Hoover (111760)
Qiuhu Shi (239318)
Jean Claude Dusingize (473718)
Jean D’Amour Sinayobye (725110)
Mardge Cohen (235024)
Kathryn Anastos (119435)

April 2015

Proportions of HIV+ ART initiators: 26.7% used AZT, 62.5% used D4T, 89.1% used NRTI total and 1.3...

Market share of AZT, TDF and TAF in first-line treatment from 2015 to 2025.

Aastha Gupta (681328)
Sandeep Juneja (3220047)
Marco Vitoria (183846)
Vincent Habiyambere (523965)
Boniface Dongmo Nguimfack (3220050)
Meg Doherty (482820)
Daniel Low-Beer (229217)

October 2016

Market share of AZT, TDF and TAF in first-line treatment from 2015 to 2025.</p

TB Incidence Rates during ART Follow-up among Patients Assessed as TB-free at ART Initiation (n = 2,325).

Andrew F. Auld (287782)
Francisco Mbofana (287784)
Ray W. Shiraishi (282434)
Charity Alfredo (287786)
Mauro Sanchez (287788)
Tedd V. Ellerbrock (287790)
Lisa J. Nelson (287791)

February 2013

TB Incidence Rates during ART Follow-up among Patients Assessed as TB-free at ART Initiation (n =...

Proportion of people starting HAART at CD4 count ≤100 cells/mm3 who failed first-line therapy and time to treatment failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.

Eduard J. Beck (301034)
Sundhiya Mandalia (60753)
Gary Lo (350911)
Peter Sharott (337278)
Mike Youle (301041)
Jane Anderson (63637)
Guy Baily (337279)
Ray Brettle (301043)
Martin Fisher (300134)
Mark Gompels (301046)
George Kinghorn (350913)
Margaret Johnson (170613)
Brendan McCarron (337280)
Anton Pozniak (272321)
Alan Tang (350914)
John Walsh (301051)
David White (350916)
Ian Williams (208301)
Brian Gazzard (4921)

February 2013

Proportion of people starting HAART at CD4 count ≤100 cells/mm3 who f...

Proportion of people starting HAART at CD4 count >350 cells/mm3 who failed first-line therapy and time to treatment failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.

Eduard J. Beck (301034)
Sundhiya Mandalia (60753)
Gary Lo (350911)
Peter Sharott (337278)
Mike Youle (301041)
Jane Anderson (63637)
Guy Baily (337279)
Ray Brettle (301043)
Martin Fisher (300134)
Mark Gompels (301046)
George Kinghorn (350913)
Margaret Johnson (170613)
Brendan McCarron (337280)
Anton Pozniak (272321)
Alan Tang (350914)
John Walsh (301051)
David White (350916)
Ian Williams (208301)
Brian Gazzard (4921)

February 2013

Proportion of people starting HAART at CD4 count >350 cells/mm3 who f...

Proportion of people starting HAART at CD4 count 201 – 350 cells/mm3 who failed first-line therapy and time to treatment failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.

Eduard J. Beck (301034)
Sundhiya Mandalia (60753)
Gary Lo (350911)
Peter Sharott (337278)
Mike Youle (301041)
Jane Anderson (63637)
Guy Baily (337279)
Ray Brettle (301043)
Martin Fisher (300134)
Mark Gompels (301046)
George Kinghorn (350913)
Margaret Johnson (170613)
Brendan McCarron (337280)
Anton Pozniak (272321)
Alan Tang (350914)
John Walsh (301051)
David White (350916)
Ian Williams (208301)
Brian Gazzard (4921)

February 2013

Proportion of people starting HAART at CD4 count 201 – 350 cells/mm3 ...

Demographic and clinical variables of active patients registered in the EMR system pre- and post-intervention.

John Haskew (362234)
Gunnar Rø (781268)
Kenrick Turner (781269)
Davies Kimanga (606394)
Martin Sirengo (781270)
Shahnaaz Sharif (489424)

August 2015

* patients eligible for ART, based on CD4 or WHO stage, but who have not started ART</...

Total proportion of patients with MDR-TB after initial attempt at diagnosis and treatment, based on varying population INHR-TB prevalence.

Kamila Romanowski (6260870)
Jonathon R. Campbell (4543495)
Olivia Oxlade (66115)
Federica Fregonese (442412)
Dick Menzies (66118)
James C. Johnston (370579)

January 2019

Total proportion of patients with MDR-TB after initial attempt at diagnosis and treatment, based on ...

Percentage of patients with various TSAT levels in the last 3 months of three studies over 14 years from 1997 to 2011.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

Percentage of patients with various TSAT levels in the last 3 months of three studies over 14 yea...

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clinical stage (left) and CD4 cell count (right).

Fabienne Shumbusho (369912)
Johan van Griensven (333866)
David Lowrance (318136)
Innocent Turate (369913)
Mark A. Weaver (369914)
Jessica Price (369915)
Agnes Binagwaho (26709)

February 2013

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clin...

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by facility in the most recent years of data available.

Herbert C. Duber (712085)
Emily Dansereau (610260)
Samuel H. Masters (673005)
Jane Achan (145106)
Roy Burstein (673006)
Brendan DeCenso (673007)
Anne Gasasira (232652)
Gloria Ikilezi (673010)
Caroline Kisia (673011)
Felix Masiye (344814)
Pamela Njuguna (357242)
Thomas Odeny (712086)
Emelda Okiro (712087)
D. Allen Roberts (712088)
Emmanuela Gakidou (250582)

March 2015

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by facility in the most recent y...

Median CD4 (IQR) for patients initiated on ART, by adherence < or ≥95% based on drug-refill visits.

Ziad El-Khatib (354831)
David Katzenstein (182035)
Gaetano Marrone (239053)
Fatima Laher (238017)
Lerato Mohapi (158544)
Max Petzold (177356)
Lynn Morris (7883)
Anna Mia Ekström (102696)

February 2013

Median CD4 (IQR) for patients initiated on ART, by adherence < or ≥95...

First-line ART regimen by enrollment year, ARV-naïve patients (N = 70,002).

Seema T. Meloni (459667)
Charlotte A. Chang (3232419)
Geoffrey Eisen (3232416)
Toyin Jolayemi (3232422)
Bolanle Banigbe (3232410)
Prosper I. Okonkwo (3232413)
Phyllis J. Kanki (459676)

October 2016

First-line ART regimen by enrollment year, ARV-naïve patients (N = 70,002).</p

Mean CD4+ T-cell percentage (95% confidence interval) after ART initiation by regimen.

Janneke H. van Dijk (277226)
Catherine G. Sutcliffe (185370)
Francis Hamangaba (277227)
Christopher Bositis (277228)
Douglas C. Watson (277229)
William J. Moss (185392)

January 2013

Mean CD4+ T-cell percentage (95% confidence interval) after ART initiation by regimen....

Proportion of antiretroviral therapy (ART) initiation among patients attending HIV clinics in two U.S. cities as measured by ART prescriptions written before or within 7 days after index visit, August 1, 2015-March 31, 2017, by selected patient characteristics.

Mary Spink Neumann (5824034)
Aaron Plant (5433278)
Andrew D. Margolis (130004)
Craig B. Borkowf (226185)
C. Kevin Malotte (271544)
Cornelis A. Rietmeijer (5824037)
Stephen A. Flores (243186)
Lydia O’Donnell (5824040)
Susan Robilotto (5824043)
Athi Myint-U (5824046)
Jorge A. Montoya (5433272)
Marjan Javanbakht (3857254)
Jeffrey D. Klausner (307922)

October 2018

Proportion of antiretroviral therapy (ART) initiation among patients attending HIV clinics in two U....

Description of ART usage among 371 women who initiated treatment.

Eugene Mutimura (239330)
Donald R. Hoover (111760)
Qiuhu Shi (239318)
Jean Claude Dusingize (473718)
Jean D’Amour Sinayobye (725110)
Mardge Cohen (235024)
Kathryn Anastos (119435)

April 2015

Proportions of HIV+ ART initiators: 26.7% used AZT, 62.5% used D4T, 89.1% used NRTI total and 1.3...

Market share of AZT, TDF and TAF in first-line treatment from 2015 to 2025.

Aastha Gupta (681328)
Sandeep Juneja (3220047)
Marco Vitoria (183846)
Vincent Habiyambere (523965)
Boniface Dongmo Nguimfack (3220050)
Meg Doherty (482820)
Daniel Low-Beer (229217)

October 2016

Market share of AZT, TDF and TAF in first-line treatment from 2015 to 2025.</p

TB Incidence Rates during ART Follow-up among Patients Assessed as TB-free at ART Initiation (n = 2,325).

Andrew F. Auld (287782)
Francisco Mbofana (287784)
Ray W. Shiraishi (282434)
Charity Alfredo (287786)
Mauro Sanchez (287788)
Tedd V. Ellerbrock (287790)
Lisa J. Nelson (287791)

February 2013

TB Incidence Rates during ART Follow-up among Patients Assessed as TB-free at ART Initiation (n =...

Proportion of people starting HAART at CD4 count ≤100 cells/mm3 who failed first-line therapy and time to treatment failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.

Eduard J. Beck (301034)
Sundhiya Mandalia (60753)
Gary Lo (350911)
Peter Sharott (337278)
Mike Youle (301041)
Jane Anderson (63637)
Guy Baily (337279)
Ray Brettle (301043)
Martin Fisher (300134)
Mark Gompels (301046)
George Kinghorn (350913)
Margaret Johnson (170613)
Brendan McCarron (337280)
Anton Pozniak (272321)
Alan Tang (350914)
John Walsh (301051)
David White (350916)
Ian Williams (208301)
Brian Gazzard (4921)

February 2013

Proportion of people starting HAART at CD4 count ≤100 cells/mm3 who f...

Proportion of people starting HAART at CD4 count >350 cells/mm3 who failed first-line therapy and time to treatment failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.

Eduard J. Beck (301034)
Sundhiya Mandalia (60753)
Gary Lo (350911)
Peter Sharott (337278)
Mike Youle (301041)
Jane Anderson (63637)
Guy Baily (337279)
Ray Brettle (301043)
Martin Fisher (300134)
Mark Gompels (301046)
George Kinghorn (350913)
Margaret Johnson (170613)
Brendan McCarron (337280)
Anton Pozniak (272321)
Alan Tang (350914)
John Walsh (301051)
David White (350916)
Ian Williams (208301)
Brian Gazzard (4921)

February 2013

Proportion of people starting HAART at CD4 count >350 cells/mm3 who f...

Proportion of people starting HAART at CD4 count 201 – 350 cells/mm3 who failed first-line therapy and time to treatment failure (days) comparing 2NRTIs+NNRTI with 2NRTIs+PIboosted first-line regimens.

Eduard J. Beck (301034)
Sundhiya Mandalia (60753)
Gary Lo (350911)
Peter Sharott (337278)
Mike Youle (301041)
Jane Anderson (63637)
Guy Baily (337279)
Ray Brettle (301043)
Martin Fisher (300134)
Mark Gompels (301046)
George Kinghorn (350913)
Margaret Johnson (170613)
Brendan McCarron (337280)
Anton Pozniak (272321)
Alan Tang (350914)
John Walsh (301051)
David White (350916)
Ian Williams (208301)
Brian Gazzard (4921)

February 2013

Proportion of people starting HAART at CD4 count 201 – 350 cells/mm3 ...

Demographic and clinical variables of active patients registered in the EMR system pre- and post-intervention.

John Haskew (362234)
Gunnar Rø (781268)
Kenrick Turner (781269)
Davies Kimanga (606394)
Martin Sirengo (781270)
Shahnaaz Sharif (489424)

August 2015

* patients eligible for ART, based on CD4 or WHO stage, but who have not started ART</...

Total proportion of patients with MDR-TB after initial attempt at diagnosis and treatment, based on varying population INHR-TB prevalence.

Kamila Romanowski (6260870)
Jonathon R. Campbell (4543495)
Olivia Oxlade (66115)
Federica Fregonese (442412)
Dick Menzies (66118)
James C. Johnston (370579)

January 2019

Total proportion of patients with MDR-TB after initial attempt at diagnosis and treatment, based on ...

Percentage of patients with various TSAT levels in the last 3 months of three studies over 14 years from 1997 to 2011.

Jonathan A. Lorch (566667)
Victor E. Pollak (566668)

May 2014

Percentage of patients with various TSAT levels in the last 3 months of three studies over 14 yea...

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clinical stage (left) and CD4 cell count (right).

Fabienne Shumbusho (369912)
Johan van Griensven (333866)
David Lowrance (318136)
Innocent Turate (369913)
Mark A. Weaver (369914)
Jessica Price (369915)
Agnes Binagwaho (26709)

February 2013

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clin...

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by year of treatment initiation.

Abstract

Extracted data

Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by year of treatment initiation.

Abstract

Extracted data

Related items

Related items